Hojuhn Song, Ph.D.
Co-Founder and Chief Executive Officer
Hojuhn is a biopharmaceutical leader and executive who has successfully led several R&D teams in start-up, and global large-pharmaceutical settings. His teams have progressed multiple novel agents through development in oncology, immune disorder, and neurodegeneration.
Before founding Pinetree Therapeutics, Inc, Hojuhn was a project team leader for novel target discovery in Functional Genomics and Developmental Molecular Pathway at Novartis Institute for Biomedical Research and successfully generated multiple clinical candidates in multiple therapeutic areas.
Hojuhn earned a Ph.D. in Genetics and Neurobiology at Oregon State University and completed a post-doctoral fellowship at Novartis AG. He received M.S in Genetics and a B.Sc. In Biology from Chungnam National University, S. Korea.
Paul is a top-tier Biotechnology Investigator and Executive with extensive strategic and leadership experience. He has demonstrated success from bench to bedside developing small molecules and biologics for oncology, autoimmunity, chronic inflammation and fibrosis.
Starting his outstanding career at Repligen and Biogen, Paul has an excellent track record of developing drugs, supported by multiple drug development campaigns with success, over 40 patents granted, and approximately 100 peer-reviewed publications. He is currently serving as President and CSO at Aleta Biotherapeutics and has been working together with Pinetree for many months as a consultant.
Bennett is an experienced financial professional who focuses on developing strategies that result into axioms for growth, profitability and value creation. His background includes executive positions at two middle-market companies, and a successful career in investment banking, having worked in some of the world's largest financial institutions.
Before joining Pinetree Therapeutics, Bennett was the CFO of US Medical Innovations, a medical device and biotech company located in Maryland. He previously held positions at Credit Suisse, Prudential, Citibank and JP Morgan, focusing on investment banking, private equity, capital markets, derivatives and M&A, where he excelled in product innovation and transaction profitability.
Bennett has an MBA in Finance from Columbia University and a BA in Economics from Harvard University.